Form 4: MDxHealth Director Hilde Windels Receives Stock Options
Statement of Changes in Beneficial Ownership
Director Hilde Windels was granted 10,000 stock options in MDxHealth SA as part of a standard equity compensation arrangement.
Summary
- Director Hilde Windels received a grant of 10,000 share options for MDxHealth SA ordinary shares.
- The options have an exercise price of $0.76 per share.
- The grant date for these options was June 1, 2026.
- The options are set to expire on May 28, 2036.
- The options vest in full on the date of the annual general shareholders' meeting in the calendar year following the grant year.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified.
Risks
- Market price volatility could impact the future value of the granted options.
- Vesting is contingent upon the director's continued association with the company until the specified annual general meeting.
Future Outlook
The options vest in full at the annual general shareholders' meeting in 2027, aligning the director's interests with the company's performance over the coming year.
Industry Context
StockSavvy.ai notes that equity grants to non-executive directors are standard corporate governance practice in the biotechnology sector to ensure board members maintain a vested interest in company performance.
Comparison to Industry Standards
- The grant of stock options to directors is consistent with standard compensation practices for publicly traded biotech companies.
- The 10-year expiration term is standard for executive and director equity incentive plans.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Hilde Windels appointed several individuals as attorneys-in-fact to handle SEC filings. | 03/02/2026 | Administrative update to ensure compliance with SEC reporting requirements. |
Related Party Transactions
- The options are held by Hilde Windels BV, an entity managed by the reporting person.
Stakeholder Impact
- Minimal impact on shareholders; reflects standard director compensation.
Next Steps
- Vesting of options at the 2027 annual general shareholders' meeting.
Key Dates
| Date | Description |
|---|---|
| 03/02/2026 | Date of Power of Attorney execution. |
| 06/01/2026 | Date of option grant and earliest transaction. |
| 06/03/2026 | Date of filing. |
| 05/28/2036 | Expiration date of the granted stock options. |
Keywords
MDxHealth, MDXH, Director Compensation, Stock Options, Insider Transaction, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.